NJ

Nikhil Jentilal Ranparia

Active Director Director DIN 11438091
DIN 11438091 First appointment Dec 2025 Primary industry Musical Instruments
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Nikhil Jentilal Ranparia

Data last updated:

Nikhil Jentilal Ranparia is a Director at Repson Biosciences Private Limited (since 2025). The company operates in Musical Instruments.

DIN 11438091
Primary Designation Director
Industry Musical Instruments
First Appointment 18 Dec 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Repson Biosciences Private Limited U24232GJ2007PTC051391
Director18 Dec 2025Active

Board colleagues of Nikhil Jentilal Ranparia

NameDINCompanyDesignation
Gouri Aditya Ganti11262967Repson Biosciences Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Repson Biosciences Private Limited
Premium access

Shareholding and investment profile for Nikhil Jentilal Ranparia

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nikhil Jentilal Ranparia

Nikhil Jentilal Ranparia currently holds 1 directorship: Repson Biosciences Private Limited (Director, since 18 Dec 2025).

Nikhil Jentilal Ranparia was first appointed on 18 Dec 2025 as Director at Repson Biosciences Private Limited.

The current boards of Nikhil Jentilal Ranparia's companies include Gouri Aditya Ganti (Repson Biosciences Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available